SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Back to Newsroom
Mentioned in this Article

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC

Tuesday, May 5, 2020 4:15 PM
Share this article now
Topic:
Lawsuits
Pomerantz LLP

NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. ("LogicBio" or the "Company") (NASDAQ:LOGC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

The investigation concerns whether LogicBio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On February 10, 2020, LogicBio issued a press release announcing that the U.S. Food and Drug Administration has placed a clinical hold on the Company's Investigational New Drug submission for its product candidate LB-001 for the treatment of methylmalonic acidemia pending the resolution of certain clinical and nonclinical questions.

On this news, LogicBio's stock price fell $3.34 per share, or 31.96%, to close at $7.11 per share on February 11, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

Back to Newsroom
Copyright 2022 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions